Interpace Biosciences Inc. (IDXG)

[retireat40]

Yes it can:

Jan. 3, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the "Company"), a company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 375,000 shares of common stock at a price of $6.75 per share and an aggregate of 255,000 pre-funded warrants to purchase common stock, at a purchase price of $6.74 per share, with $0.01 per share payable upon exercise of each pre-funded warrant, in a registered direct offering with aggregate gross proceeds of approximately $4.2 million. The offering is expected to close on or about January 6, 2017, subject to the satisfaction of customary closing conditions.

A lot of people may have gotten hosed here.